

Ribavirin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.1	14.04.2025	402764-00023	Date of first issue: 10.12.2015

SECTION 1: Identification of the substance/mixture and of the company/undertaking**1.1 Product identifier**

Trade name : Ribavirin Liquid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-
stance/Mixture : Pharmaceutical

Recommended restrictions
on use : Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD
117 16th Road
1685 Halfway house, Midrand, South Africa

Telephone : +27 11 655 3000

E-mail address of person
responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification**2.1 Classification of the substance or mixture****Classification (REGULATION (EC) No 1272/2008)**

Germ cell mutagenicity, Category 2
Reproductive toxicity, Category 1B

Specific target organ toxicity - repeated
exposure, Category 2

H341: Suspected of causing genetic defects.
H360Df: May damage the unborn child. Suspected
of damaging fertility.
H373: May cause damage to organs through pro-
longed or repeated exposure.

2.2 Label elements**Labelling (REGULATION (EC) No 1272/2008)**

Hazard pictograms :



Signal word : Danger

Hazard statements : H341 Suspected of causing genetic defects.
H360Df May damage the unborn child. Suspected of damaging

Ribavirin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.1	14.04.2025	402764-00023	Date of first issue: 10.12.2015

fertility.

H373 May cause damage to organs through prolonged or repeated exposure.

Precautionary statements :

Prevention:

P201 Obtain special instructions before use.

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Hazardous components which must be listed on the label:

Ribavirin

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients**3.2 Mixtures****Components**

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Ribavirin	36791-04-5	Acute Tox. 4; H302 Muta. 2; H341 Repr. 1B; H360Df STOT SE 3; H335 STOT RE 1; H372 (Blood)	>= 1 - < 10

For explanation of abbreviations see section 16.

SECTION 4: First aid measures**4.1 Description of first aid measures**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

Ribavirin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.1	14.04.2025	402764-00023	Date of first issue: 10.12.2015

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

- | | | |
|-------------------------|---|---|
| If inhaled | : | If inhaled, remove to fresh air.
Get medical attention. |
| In case of skin contact | : | In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse. |
| In case of eye contact | : | Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists. |
| If swallowed | : | If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water. |

4.2 Most important symptoms and effects, both acute and delayed

- | | | |
|-------|---|--|
| Risks | : | Suspected of causing genetic defects.
May damage the unborn child. Suspected of damaging fertility.
May cause damage to organs through prolonged or repeated exposure. |
|-------|---|--|

4.3 Indication of any immediate medical attention and special treatment needed

- | | | |
|-----------|---|---|
| Treatment | : | Treat symptomatically and supportively. |
|-----------|---|---|

SECTION 5: Firefighting measures**5.1 Extinguishing media**

- | | | |
|--------------------------------|---|--|
| Suitable extinguishing media | : | Water spray
Alcohol-resistant foam
Carbon dioxide (CO ₂)
Dry chemical |
| Unsuitable extinguishing media | : | None known. |

5.2 Special hazards arising from the substance or mixture

- | | | |
|---------------------------------------|---|--|
| Specific hazards during fire-fighting | : | Exposure to combustion products may be a hazard to health. |
| Hazardous combustion products | : | Carbon oxides |

5.3 Advice for firefighters

- | | | |
|------------------------------|---|--|
| Special protective equipment | : | In the event of fire, wear self-contained breathing apparatus. |
|------------------------------|---|--|

Ribavirin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.1	14.04.2025	402764-00023	Date of first issue: 10.12.2015

for firefighters	Use personal protective equipment.
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures**6.1 Personal precautions, protective equipment and emergency procedures**

Personal precautions	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
----------------------	--

6.2 Environmental precautions

Environmental precautions	: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
---------------------------	--

6.3 Methods and material for containment and cleaning up

Methods for cleaning up	: Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
-------------------------	---

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage**7.1 Precautions for safe handling**

Technical measures	: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	: If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	: Do not get on skin or clothing. Do not breathe mist or vapours.

Ribavirin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.1	14.04.2025	402764-00023	Date of first issue: 10.12.2015

Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:
Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides
Explosives
Gases

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection**8.1 Control parameters****Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Sucrose	57-50-1	OEL-RL	10 mg/m ³	ZA OEL
Further information: Occupational Exposure Limits - Restricted Limits For Hazardous Chemical Agents				
Ribavirin	36791-04-5	Wipe limit	400 µg/100 cm ²	Internal
		TWA	40 µg/m ³ (OEB 3)	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects	Value
Propylene glycol	Workers	Inhalation	Long-term local ef-	10 mg/m ³

Ribavirin Liquid Formulation

Version 5.1 Revision Date: 14.04.2025 SDS Number: 402764-00023 Date of last issue: 06.04.2024
 Date of first issue: 10.12.2015

			fects	
	Workers	Inhalation	Long-term systemic effects	168 mg/m3
	Consumers	Inhalation	Long-term local effects	10 mg/m3
	Consumers	Inhalation	Long-term systemic effects	50 mg/m3
Glycerine	Workers	Inhalation	Long-term local effects	56 mg/m3
	Consumers	Ingestion	Long-term systemic effects	229 mg/kg bw/day
	Consumers	Inhalation	Long-term local effects	33 mg/m3

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Propylene glycol	Fresh water	260 mg/l
	Freshwater - intermittent	183 mg/l
	Marine water	26 mg/l
	Sewage treatment plant	20000 mg/l
	Fresh water sediment	572 mg/kg dry weight (d.w.)
	Marine sediment	57,2 mg/kg dry weight (d.w.)
	Soil	50 mg/kg dry weight (d.w.)
Glycerine	Fresh water	0,885 mg/l
	Marine water	0,0885 mg/l
	Intermittent use/release	8,85 mg/l
	Sewage treatment plant	1000 mg/l
	Fresh water sediment	3,3 mg/kg dry weight (d.w.)
	Marine sediment	0,33 mg/kg dry weight (d.w.)
	Soil	0,141 mg/kg dry weight (d.w.)

8.2 Exposure controls**Engineering measures**

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
 Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

Ribavirin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.1	14.04.2025	402764-00023	Date of first issue: 10.12.2015

Hand protection	aerosols.
Material	: Chemical-resistant gloves
Remarks	: Consider double gloving.
Skin and body protection	: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	: Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties**9.1 Information on basic physical and chemical properties**

Appearance	: liquid
Colour	: clear
Odour	: No data available
Odour Threshold	: No data available
pH	: 4,8 - 5,5
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapour pressure	: No data available
Relative vapour density	: No data available
Relative density	: No data available
Density	: No data available
Solubility(ies)	

Ribavirin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.1	14.04.2025	402764-00023	Date of first issue: 10.12.2015

Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

9.2 Other information

Particle size	:	Not applicable
---------------	---	----------------

SECTION 10: Stability and reactivity**10.1 Reactivity**

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions	:	Can react with strong oxidizing agents.
---------------------	---	---

10.4 Conditions to avoid

Conditions to avoid	:	None known.
---------------------	---	-------------

10.5 Incompatible materials

Materials to avoid	:	Oxidizing agents
--------------------	---	------------------

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information**11.1 Information on toxicological effects**

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
--	---	--

Acute toxicity

Not classified based on available information.

Product:

Ribavirin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.1	14.04.2025	402764-00023	Date of first issue: 10.12.2015

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg
Method: Calculation method

Components:**Ribavirin:**

Acute oral toxicity : LD50 (Rat): 4.116 - 5.584 mg/kg
LD50 (Mouse): > 10.000 mg/kg
LD50 (Dog): >= 1.500 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): 1.554 - 1.758 mg/kg
Application Route: Intraperitoneal
LD50 (Mouse): 1.268 mg/kg
Application Route: Intraperitoneal

Skin corrosion/irritation

Not classified based on available information.

Components:**Ribavirin:**

Remarks : No data available
May irritate skin.

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Ribavirin:**

Remarks : No data available
May irritate eyes.

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Ribavirin:**

Remarks : No data available

Ribavirin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.1	14.04.2025	402764-00023	Date of first issue: 10.12.2015

Germ cell mutagenicity

Suspected of causing genetic defects.

Components:**Ribavirin:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: In vitro mammalian cell gene mutation test Test system: Rodent cell line Result: positive Test Type: Chromosomal aberration Test system: Human lymphocytes Result: negative
Genotoxicity in vivo	:	Test Type: dominant lethal test Species: Rat Result: negative Test Type: Mouse Lymphoma Species: Mouse Result: positive Test Type: Micronucleus test Species: Mouse Result: positive
Germ cell mutagenicity- Assessment	:	Positive result(s) from in vivo mammalian somatic cell mutagenicity tests.

Carcinogenicity

Not classified based on available information.

Components:**Ribavirin:**

Species	:	Mouse
Application Route	:	Oral
Exposure time	:	6 Months
LOAEL	:	75 mg/kg body weight
Result	:	negative
Target Organs	:	Blood, Testes
Remarks	:	The mechanism or mode of action may not be relevant in humans.
Species	:	Rat
Application Route	:	Oral
Exposure time	:	2 Years
NOAEL	:	10 mg/kg body weight
Result	:	negative
Remarks	:	The mechanism or mode of action may not be relevant in humans.

Ribavirin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.1	14.04.2025	402764-00023	Date of first issue: 10.12.2015

Species	:	Mouse
Application Route	:	Oral
Exposure time	:	18 Months
Result	:	negative
Remarks	:	The mechanism or mode of action may not be relevant in humans.

Reproductive toxicity

May damage the unborn child. Suspected of damaging fertility.

Components:**Ribavirin:**

Effects on fertility	:	Test Type: Fertility Species: Rat, male Application Route: Intraperitoneal injection Fertility: LOAEL: < 20 mg/kg body weight Symptoms: Reduced fertility Result: positive Test Type: Fertility Species: Mouse, male Application Route: Oral Fertility: LOAEL: 35 mg/kg body weight Symptoms: Reduced fertility Result: positive Test Type: Fertility Species: Rat, females Application Route: Oral Fertility: NOAEL: 10 mg/kg body weight Result: Animal testing did not show any effects on fertility. Test Type: Fertility Species: Rat, male Application Route: Oral Fertility: NOAEL: 160 mg/kg body weight Result: Animal testing did not show any effects on fertility.
Effects on foetal development	:	Test Type: Development Species: Rat, female Application Route: Oral Developmental Toxicity: LOAEL: <= 1 mg/kg body weight Symptoms: Reduced body weight, Reduced number of viable fetuses, Skeletal malformations Result: Embryotoxic effects and adverse effects on the offspring were detected. Test Type: Development Species: Rabbit, female Application Route: Oral General Toxicity Maternal: LOAEL: 1 mg/kg body weight Developmental Toxicity: LOAEL: 1 mg/kg body weight Symptoms: Reduced body weight, Skeletal malformations Result: Embryotoxic effects and adverse effects on the off-

Ribavirin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.1	14.04.2025	402764-00023	Date of first issue: 10.12.2015

spring were detected.

Test Type: Development
Species: Hamster
Application Route: Oral
Developmental Toxicity: LOAEL: 2,5 mg/kg body weight
Symptoms: Skeletal and visceral variations, Total Resorptions / resorption rate
Result: Embryotoxic effects and adverse effects on the off-spring were detected.

Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
General Toxicity Maternal: NOAEL: 0,3 mg/kg body weight
Embryo-foetal toxicity: LOAEL: 1 mg/kg body weight
Symptoms: Skeletal malformations
Result: positive

Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.

STOT - single exposure

Not classified based on available information.

Components:**Ribavirin:**

Assessment : May cause respiratory irritation.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:**Ribavirin:**

Exposure routes : Ingestion
Target Organs : Blood
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Ribavirin:**

Species : Monkey
LOAEL : 30 mg/kg
Exposure time : 10 d
Target Organs : Blood, Gastrointestinal tract

Species : Rat
NOAEL : 7,6 mg/kg

Ribavirin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.1	14.04.2025	402764-00023	Date of first issue: 10.12.2015

Application Route	:	Inhalation
Exposure time	:	90 d
Target Organs	:	Blood, Lungs
Species	:	Dog
NOAEL	:	5 mg/kg
Application Route	:	Oral
Exposure time	:	1 yr
Target Organs	:	Blood, Gastrointestinal tract
Species	:	Mouse
NOAEL	:	20 mg/kg
Application Route	:	Oral
Exposure time	:	18 Months
Target Organs	:	Blood, Cardio-vascular system

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Ribavirin:**

Inhalation	:	Symptoms: Headache, Dizziness Remarks: Based on Human Evidence
Skin contact	:	Remarks: May cause eye irritation. Based on Human Evidence
Eye contact	:	Remarks: May cause eye irritation. Based on Human Evidence
Ingestion	:	Symptoms: blood effects, immune system effects, anorexia, Dizziness, insomnia, Fatigue, Headache, Itching, Rash, liver function change, Gastrointestinal disturbance

SECTION 12: Ecological information**12.1 Toxicity****Components:****Ribavirin:**

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): > 119 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 117 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 119 mg/l Exposure time: 96 h Method: OECD Test Guideline 201
		NOEC (Pseudokirchneriella subcapitata (green algae)): 6,9 mg/l

Ribavirin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.1	14.04.2025	402764-00023	Date of first issue: 10.12.2015

Exposure time: 96 h
Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50 : > 1.000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential**Components:****Ribavirin:**

Partition coefficient: n- : log Pow: 0,971
octanol/water

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment**Product:**

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects**Product:**

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations**13.1 Waste treatment methods**

Product : Dispose of in accordance with local regulations.
According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.
Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.
Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Ribavirin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.1	14.04.2025	402764-00023	Date of first issue: 10.12.2015

SECTION 14: Transport information**14.1 UN number**

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Not regulated as a dangerous good

14.2 UN proper shipping name

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Not regulated as a dangerous good

14.4 Packing group

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA (Cargo)	:	Not regulated as a dangerous good
IATA (Passenger)	:	Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

Ribavirin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.1	14.04.2025	402764-00023	Date of first issue: 10.12.2015

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
-------------------	---	--

Full text of H-Statements

H302	:	Harmful if swallowed.
H335	:	May cause respiratory irritation.
H341	:	Suspected of causing genetic defects.
H360Df	:	May damage the unborn child. Suspected of damaging fertility.
H372	:	Causes damage to organs through prolonged or repeated exposure if swallowed.

Full text of other abbreviations

Acute Tox.	:	Acute toxicity
Muta.	:	Germ cell mutagenicity
Repr.	:	Reproductive toxicity
STOT RE	:	Specific target organ toxicity - repeated exposure
STOT SE	:	Specific target organ toxicity - single exposure
ZA OEL	:	South Africa. The Regulations for Hazardous Chemical Agents, Occupational Exposure Limits
ZA OEL / OEL-RL	:	Occupational Exposure Limit Restricted limit - 8- hour exposure or equivalent (12 hour shifts)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air

Ribavirin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.1	14.04.2025	402764-00023	Date of first issue: 10.12.2015

Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECL - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Muta. 2	H341
Repr. 1B	H360Df
STOT RE 2	H373

Classification procedure:

Calculation method
Calculation method
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN